332 related articles for article (PubMed ID: 26971534)
1. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
[TBL] [Abstract][Full Text] [Related]
2. Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange.
Leu K; Boxerman JL; Cloughesy TF; Lai A; Nghiemphu PL; Liau LM; Pope WB; Ellingson BM
AJNR Am J Neuroradiol; 2016 Aug; 37(8):1440-6. PubMed ID: 27079371
[TBL] [Abstract][Full Text] [Related]
3. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
4. Validation of a T1 and T2* leakage correction method based on multiecho dynamic susceptibility contrast MRI using MION as a reference standard.
Stokes AM; Semmineh N; Quarles CC
Magn Reson Med; 2016 Aug; 76(2):613-25. PubMed ID: 26362714
[TBL] [Abstract][Full Text] [Related]
5. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
6. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.
Bennett IE; Field KM; Hovens CM; Moffat BA; Rosenthal MA; Drummond K; Kaye AH; Morokoff AP
J Neurooncol; 2017 Jan; 131(2):321-329. PubMed ID: 27896520
[TBL] [Abstract][Full Text] [Related]
7. Effect of Applying Leakage Correction on rCBV Measurement Derived From DSC-MRI in Enhancing and Nonenhancing Glioma.
Arzanforoosh F; Croal PL; van Garderen KA; Smits M; Chappell MA; Warnert EAH
Front Oncol; 2021; 11():648528. PubMed ID: 33869047
[TBL] [Abstract][Full Text] [Related]
8. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
[TBL] [Abstract][Full Text] [Related]
10. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
[TBL] [Abstract][Full Text] [Related]
11. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.
Schmainda KM; Prah M; Connelly J; Rand SD; Hoffman RG; Mueller W; Malkin MG
Neuro Oncol; 2014 Jun; 16(6):880-8. PubMed ID: 24431219
[TBL] [Abstract][Full Text] [Related]
12. Consistency of normalized cerebral blood volume values in glioblastoma using different leakage correction algorithms on dynamic susceptibility contrast magnetic resonance imaging data without and with preload.
Hedderich D; Kluge A; Pyka T; Zimmer C; Kirschke JS; Wiestler B; Preibisch C
J Neuroradiol; 2019 Feb; 46(1):44-51. PubMed ID: 29753641
[TBL] [Abstract][Full Text] [Related]
13. Is Weisskoff model valid for the correction of contrast agent extravasation with combined T1 and T2* effects in dynamic susceptibility contrast MRI?
Liu HL; Wu YY; Yang WS; Chen CF; Lim KE; Hsu YY
Med Phys; 2011 Feb; 38(2):802-9. PubMed ID: 21452717
[TBL] [Abstract][Full Text] [Related]
14. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
[TBL] [Abstract][Full Text] [Related]
15. Systematic assessment of multi-echo dynamic susceptibility contrast MRI using a digital reference object.
Stokes AM; Semmineh NB; Nespodzany A; Bell LC; Quarles CC
Magn Reson Med; 2020 Jan; 83(1):109-123. PubMed ID: 31400035
[TBL] [Abstract][Full Text] [Related]
16. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
17. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.
Leu K; Enzmann DR; Woodworth DC; Harris RJ; Tran AN; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
Cancer Imaging; 2014 Nov; 14(1):31. PubMed ID: 25608485
[TBL] [Abstract][Full Text] [Related]
18. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
[TBL] [Abstract][Full Text] [Related]
19. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
[TBL] [Abstract][Full Text] [Related]
20. The impact of EPI-based distortion correction of dynamic susceptibility contrast MRI on cerebral blood volume estimation in patients with glioblastoma.
Hovden IT; Geier OM; Digernes I; Fuster-Garcia E; Løvland G; Vik-Mo E; Meling TR; Emblem KE
Eur J Radiol; 2020 Nov; 132():109278. PubMed ID: 33010685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
